Modelling and control of HIV dynamics

Various models of HIV infection and evolution have been considered in the literature. This paper considers a variant of the Wodarz and Nowak mathematical model, adding "aggressiveness" as a new state variable in order to quantify the strength of the virus and its response to drugs. Although the model proposed is relatively simple, simulation results suggest that it may be useful in predicting the impact of the effectiveness of therapy on HIV dynamics.

[1]  M. Martin-Landrove,et al.  A model for continuously mutant HIV-1 , 2000, Proceedings of the 22nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society (Cat. No.00CH37143).

[2]  A. Abbas,et al.  Cellular and Molecular Immunology , 1991 .

[3]  Xiaohua Xia,et al.  Estimation of HIV/AIDS parameters , 2003, Autom..

[4]  Alain Mallet,et al.  A modeling approach to the impact of HIV mutations on the immune system , 2005, Comput. Biol. Medicine.

[5]  D. Cooper,et al.  Impact of early HIV-1 RNA and T-lymphocyte dynamics during primary HIV-1 infection on the subsequent course of HIV-1 RNA levels and CD4+ T-lymphocyte counts in the first year of HIV-1 infection. Sydney Primary HIV Infection Study Group. , 1999, Journal of acquired immune deficiency syndromes.

[6]  Impact of early HIV-1 RNA and T-lymphocyte dynamics during primary HIV-1 infection on the subsequent course of HIV-1 RNA levels and CD4+ T-lymphocyte counts in the first year of HIV-1 infection. Sydney Primary HIV Infection Study Group. , 1999, Journal of acquired immune deficiency syndromes.

[7]  A. Fauci,et al.  New concepts in the immunopathogenesis of HIV infection. , 1995, Annual review of immunology.

[8]  E. Rosenberg,et al.  Fully Differentiated HIV-1 Specific CD8+ T Effector Cells Are More Frequently Detectable in Controlled than in Progressive HIV-1 Infection , 2007, PloS one.

[9]  Martin A Nowak,et al.  Mathematical models of HIV pathogenesis and treatment. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[10]  E. Arts,et al.  A Dual Infection/Competition Assay Shows a Correlation between Ex Vivo Human Immunodeficiency Virus Type 1 Fitness and Disease Progression , 2000, Journal of Virology.

[11]  B. Adams,et al.  HIV dynamics: Modeling, data analysis, and optimal treatment protocols , 2005 .

[12]  Todd M. Allen,et al.  HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication , 2004, The Lancet.

[13]  F. Mazzotta,et al.  Correlation between plasma HIV-1 RNA levels and the rate of immunologic decline. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[14]  Ryan Zurakowski,et al.  A model predictive control based scheduling method for HIV therapy. , 2006, Journal of theoretical biology.

[15]  S. Deeks,et al.  When to Start Antiretroviral Therapy , 2010, Current HIV/AIDS reports.

[16]  Jose M. Pinto,et al.  Role of mathematical modeling on the optimal control of HIV-1 pathogenesis , 2006 .

[17]  J. Prins,et al.  Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type I: established and potential determinants of virological outcome. , 2004, The Netherlands journal of medicine.

[18]  M. Nowak,et al.  Specific therapy regimes could lead to long-term immunological control of HIV. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Estimating the viral load response time after HIV chemotherapy , 2002, IEEE AFRICON. 6th Africon Conference in Africa,.

[20]  Guanrong Chen,et al.  Feedback control of a biodynamical model of HIV-1 , 2001, IEEE Transactions on Biomedical Engineering.

[21]  M. Nowak,et al.  Population Dynamics of Immune Responses to Persistent Viruses , 1996, Science.

[22]  Ruy M Ribeiro,et al.  Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. , 2004, Mathematical biosciences.

[23]  I. Craig,et al.  Can HIV/AIDS be controlled? Applying control engineering concepts outside traditional fields , 2005, IEEE Control Systems.

[24]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[25]  D. Ho,et al.  An Antigenic Threshold for Maintaining Human Immunodeficiency Virus Type 1-specific Cytotoxic T Lymphocytes , 2000, Molecular medicine.

[26]  M. Nowak,et al.  Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy , 1999, Journal of Virology.

[27]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.